RASSF4 and Miyoshi myopathy: Although RAS mutations are frequently observed in MM and drive oncogenic signaling through pathways such as MEK/ERK and PI3K/AKT, Eva et.al indicate that the tumor-suppressive function of RASSF4 remains intact irrespective of RAS mutational status.